Suppr超能文献

他克林和卵磷脂治疗轻至中度阿尔茨海默病的疗效:双盲试验。

Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial.

作者信息

Maltby N, Broe G A, Creasey H, Jorm A F, Christensen H, Brooks W S

机构信息

University of Sydney, Department of Geriatric Medicine, Repatriation General Hospital, Concord, Australia.

出版信息

BMJ. 1994 Apr 2;308(6933):879-83. doi: 10.1136/bmj.308.6933.879.

Abstract

OBJECTIVE

To assess the efficacy of tacrine and lecithin in treating Alzheimer's disease over nine months.

DESIGN

Double blind randomised controlled trial.

SETTING

Outpatients clinic of university department of geriatric medicine.

SUBJECTS

53 subjects (26 women, 27 men) with probable Alzheimer's disease. 41 completed the dose finding phase and were randomised to treatment. 32 (14 tacrine, 18 placebo) completed nine months' treatment.

INTERVENTIONS

Lecithin and tacrine or lecithin and placebo for 36 weeks.

MAIN OUTCOME MEASURES

Scores on neuropsychological tests sensitive to deficits in the cholinergic system; mini-mental state score; behaviour change; mood; functional state; and stress in carers.

RESULTS

The tacrine and placebo groups were similar except that the tacrine group had a longer duration of disease (mean 5.4 v 2.5 years in placebo group; P = 0.003). Only 17 of the 32 patients could tolerate the maximum dose of tacrine (100 mg). No significant difference was found between the groups for any of the tests after nine months' treatment except for the digit backwards test, which is insensitive to cholinergic deficit. Analysis of subjects taking the maximum dose of tacrine and of subjects with mild dementia also found no differences.

CONCLUSIONS

Tacrine produces no clinically relevant improvement over 36 weeks at the doses tolerated by these patients.

摘要

目的

评估他克林和卵磷脂治疗阿尔茨海默病九个月的疗效。

设计

双盲随机对照试验。

地点

大学老年医学科门诊。

研究对象

53名可能患有阿尔茨海默病的受试者(26名女性,27名男性)。41名完成了剂量探索阶段并被随机分组接受治疗。32名(14名服用他克林,18名服用安慰剂)完成了九个月的治疗。

干预措施

卵磷脂和他克林或卵磷脂和安慰剂治疗36周。

主要观察指标

对胆碱能系统缺陷敏感的神经心理学测试得分;简易精神状态评分;行为改变;情绪;功能状态;以及照顾者的压力。

结果

他克林组和安慰剂组相似,只是他克林组的病程更长(安慰剂组平均病程为2.5年,他克林组为5.4年;P = 0.003)。32名患者中只有17名能够耐受他克林的最大剂量(100毫克)。九个月治疗后,除对胆碱能缺陷不敏感的倒背数字测试外,两组在任何测试中均未发现显著差异。对服用他克林最大剂量的受试者和轻度痴呆受试者的分析也未发现差异。

结论

在这些患者能够耐受的剂量下,他克林在36周内未产生临床上相关的改善。

相似文献

3
Tacrine in Alzheimer's disease.他克林用于治疗阿尔茨海默病。
Lancet. 1991 Apr 27;337(8748):989-92. doi: 10.1016/0140-6736(91)92656-m.

引用本文的文献

5
Tacrine for Alzheimer's disease. Costs and benefits.他克林用于治疗阿尔茨海默病。成本与效益。
Pharmacoeconomics. 1995 Apr;7(4):275-9. doi: 10.2165/00019053-199507040-00001.
9
Recent advances in geriatric psychopharmacology.老年精神药理学的最新进展。
Drugs Aging. 1995 Sep;7(3):184-202. doi: 10.2165/00002512-199507030-00004.
10
Tetrahydroaminoacridine and Alzheimer's disease.四氢氨基吖啶与阿尔茨海默病
BMJ. 1994 Apr 2;308(6933):868-9. doi: 10.1136/bmj.308.6933.868.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验